AN2 Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 15.32 million compared to USD 7.66 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 2.98 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.015 USD | +0.75% |
|
+2.51% | -90.04% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-90.04% | 59.66M | |
+35.23% | 51.07B | |
-7.50% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+12.19% | 26.35B | |
-18.61% | 19.46B | |
+41.14% | 13.58B | |
+29.74% | 12.46B | |
-3.32% | 11.75B |
- Stock Market
- Equities
- ANTX Stock
- News AN2 Therapeutics, Inc.
- AN2 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023